ANEB vs BIO · $15.3M cap vs rev $2.58B
Anebulo Pharmaceuticals Inc (ANEB) versus BIO (BIO) — a side-by-side from cached financials, not a winner call.
Anebulo Pharmaceuticals Inc (ANEB) is a biotechnology company listed on US.
BIO (BIO) common stock.
ANEB does not have a complete income-statement cache yet.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
ANEB currently screens at market cap $15.3M. BIO currently screens at market cap $0.
Not investment advice. Open the ANEB and BIO stock pages for the full models.
Not investment advice.